Form 8.3 - Horizon Therapeutics plc

LONDON--(BUSINESS WIRE)-- 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Millennium International Management LP
Company dealt in	Horizon Therapeutics plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	IE00BQPVQZ61
Date of dealing	8^th February 2023

2. INTERESTS AND SHORT POSITIONS

1. Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	4,988,490 (2.181%)		23,873 (0.010%)
(2) Derivatives (other than options)			621 (0.000%)
(3) Options and agreements to purchase/sell	75,000 (0.033%)		152,200 (0.067%)
Total	5,063,490 (2.213%)		176,694 (0.077%)

b. Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

3. DEALINGS (Note 4)

1. Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase	4,000	109.90
Sale	50	109.78
Purchase	50	109.76
Sale	100	109.76
Sale	50	109.75
Purchase	190	109.79
Purchase	100	109.77
Sale	200	109.69
Purchase	50	109.86
Sale	50	109.91
Sale	900	109.70
Sale	100	109.63
Purchase	2,374	109.60
Purchase	104	109.68
Sale	100	109.68
Sale	108	109.66
Sale	106	109.62
Sale	100	109.61
Sale	100	109.65
Sale	894	109.67
Purchase	257	109.99
Sale	4	109.78
Sale	2	109.76
Sale	18	109.79
Sale	2	109.77
Sale	102	110.01
Sale	200	109.91
Sale	2	110.04
Sale	10	109.85
Sale	2	110.02
Purchase	363	109.60
Sale	2	109.60
Sale	8	109.94
Purchase	1,168	109.78
Purchase	684	109.76
Purchase	807	109.75
Purchase	288	109.79
Sale	190	109.79
Purchase	800	109.80
Sale	14	109.80
Purchase	577	109.71
Sale	200	109.71
Purchase	1,716	109.77
Sale	578	109.99
Purchase	272	109.69
Sale	153	109.69
Purchase	27	109.84
Purchase	1,737	109.83
Sale	110	110.01
Purchase	1,223	109.64
Purchase	850	109.82
Sale	100	109.82
Sale	100	109.90
Purchase	2,514	109.86
Sale	20	109.86
Purchase	83	109.81
Sale	80	110.04
Purchase	152	109.70
Purchase	519	109.85
Purchase	1,634	109.74
Sale	100	109.74
Sale	172	110.02
Sale	72	109.98
Purchase	1,519	109.63
Sale	87	109.63
Sale	300	109.60
Sale	511	109.87
Sale	40	109.95
Purchase	298	109.68
Sale	606	109.68
Purchase	212	109.66
Sale	50	109.66
Purchase	400	109.88
Sale	66	109.94
Purchase	21	109.62
Purchase	20	109.61
Sale	80	109.96
Sale	134	109.89
Sale	50	109.97
Sale	18	110.03
Purchase	2,046	109.67
Sale	12	109.67
Sale	11	109.75
Sale	7	109.79
Sale	18	109.80
Sale	12	109.71
Sale	4	109.77
Sale	14	109.69
Sale	7	109.64
Sale	8	109.86
Sale	65	109.91
Sale	7	109.74
Sale	14	110.02
Sale	4	109.63
Sale	8	109.60
Sale	7	109.95
Sale	6	109.68
Sale	2	109.66
Sale	1	109.62
Sale	10	109.96
Sale	90	109.79
Purchase	2,653	109.73
Purchase	470	109.99
Sale	2,887	109.84
Purchase	5	109.64
Sale	38	109.87

b. Derivatives transactions (other than options transactions)

Product name, e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (USD) (Note 5)

c. Options transactions in respect of existing relevant securities

1. Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price (USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

ii. Exercising

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

d. Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)

Details

Price per unit (if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure	9^th February 2023
Contact name	Roisin Nagle
Telephone number	[phone]
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making disclosure:	Millennium International Management LP
Name of offeror/offeree in relation to whose relevant securities the disclosure relates:	Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of relevant security	Product description e.g. call option	Written or purchased	Number of securities to which option or derivative relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date
IE00BQPVQZ61	Call Option	Written	29,000	110.00	American	2/17/2023
IE00BQPVQZ61	Call Option	Purchased	29,100	100.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	1,500	90.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	3,000	110.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Written	3,000	115.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	42,500	120.00	American	5/19/2023
IE00BQPVQZ61	Call Option	Purchased	400	115.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	400	115.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	110.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	62,400	110.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	4,100	80.00	American	5/19/2023
IE00BQPVQZ61	Put Option	Purchased	3,500	110.00	American	3/17/2023
IE00BQPVQZ61	Put Option	Purchased	3,100	85.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	2,500	90.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	100	95.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	23,800	100.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	14,500	105.00	American	2/17/2023
IE00BQPVQZ61	Put Option	Purchased	400	80.00	American	1/17/2025
IE00BQPVQZ61	Put Option	Purchased	400	90.00	American	1/19/2024

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.